順絡電子(002138.SZ):終止2020年度非公開發行股票事項並申請撤回申請材料
格隆匯 11 月 18日丨順絡電子(002138.SZ)公佈,公司於2020年11月18日分別召開了第五屆董事會第三十六次會議、第五屆監事會第二十六次會議,審議通過了《關於終止公司2020年度非公開發行股票事項並申請撤回申請材料的議案》,決定終止公司2020年度非公開發行股票事項,並向中國證監會申請撤回非公開發行股票申請材料。
鑑於資本市場環境的變化,經公司綜合內外部因素,並與中介機構等深入溝通和審慎分析,公司決定終止2020年度非公開發行股票事項,並向中國證監會申請撤回相關申請材料。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.